Matthew Pillar

Matthew Pillar is chief editor at BioProcess Online. He's spent the past 20 years covering tech-centric industries as they’ve navigated AI, machine learning, IoT, and other emerging technologies. His chief and executive editorial experience includes tenures with Software Executive, Channel Executive, Business Solutions and ISR magazines, where he routinely interviewed international technology builders and influencers. Pillar has spoken on emerging technologies and their implications at major events for leading tech vendors including NetSuite, Oracle, SAP, and others.

Connect with Pillar on LinkedIn at linkedin.com/in/matthewpillar/

ARTICLES BY MATTHEW PILLAR

Biologics Clinical Research: The Year’s Best
How Computational Biology Birthed A Biopharma
Your Drug Development Team Holds The Key To The Clinic
Can GDF11 Address Aging, One Disease At A Time?
Reshaping The Vaccine Manufacturing Paradigm
Regulatory Approval Shifts In The Age Of COVID-19
How Computational Drug Discovery Is Disrupting Biopharma
A Differentiated Approach To Allogeneic Cell Therapy Manufacturing
Tackling The Cell & Gene Manufacturing Talent Crunch
Taking On The Talent Crunch In Biopharma, Cell & Gene Manufacturing
Keeping Clinicals On-Pace In The COVID-19 Age
Dr. Bobby Gaspar On Manufacturing, Commercialization Challenges
$2,000-Per-Dose Cell Therapy In The Clinic
Beating The AAV Vector Immunogenicity Challenge
Renewed Innovation In Vaccine Development
Beating Stem Cell Sourcing, Exosome Production Challenges
Clinical Logistics: Keeping COVID-19 Vaccine, Therapeutic Dev On The Rails
Is Your Definition Of Quality Culture The Same As The FDA's?
The Biopharma Supply Chain Under The Biden Administration
Inside AVROBIO’s Approach To Gene Therapy Manufacturing Automation
Pursuing A Microbial Therapeutic Modality
3 Keys To Biopharma Finance Leadership
COVID-19 Consortium: Competitive Collab On A Plasma-Derived Therapy
AGTC Goes Mobile To Avoid Clinical Trial Chaos
Next Steps For AI, Machine Learning In Biopharma